One-week treatment with once-daily fluorouracil cream 0.5% in participants with actinic keratoses

Baylor University Medical Center, Division of Dermatology, Dallas, TX 75246, USA.
Cutis; cutaneous medicine for the practitioner (Impact Factor: 0.72). 07/2008; 81(6):509-16.
Source: PubMed

ABSTRACT Actinic keratoses (AKs) are common in fair-skinned individuals with a history of chronic and excessive sun exposure and may progress to squamous cell carcinoma (SCC). Topical fluorouracil is an effective therapeutic option for patients with AKs, but it is associated with substantial skin irritation. The efficacy and tolerability of 1-week treatment using microsponge-based fluorouracil cream 0.5% were analyzed in 356 participants with AK lesions. One-week treatment with once-daily fluorouracil cream 0.5% was significantly more effective than vehicle control in reducing AK lesions and in achieving complete clearance (P<.001). No serious treatment-related adverse events occurred. The most frequent treatment-related adverse events were facial and eye irritations, which were predominantly mild to moderate in severity. No participants in the fluorouracil cream 0.5% treatment group discontinued the study because of treatment-related adverse events. One-week treatment with once-daily fluorouracil cream 0.5% is an effective well-tolerated therapy for AKs. Using this short treatment duration period in combination with cryosurgery may prove beneficial in clinical practice. Extending treatment for up to 4 weeks will further improve AK lesion clearance rates.

8 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Topical drug application is less prone to severe systemic side-effects than systemic application. Starting with the liposomes, various types of nanosized and microsized drug carriers have been developed to increase the notoriously low penetration of active agents into the skin, which limits not only the topical therapy of skin disease but also transdermal therapy. Today, liposome- and microsponge-based preparations are approved for dermatomycosis, acne and actinic keratosis. Under investigation are drug carriers such as lipid nanoparticles, polymeric particles, dendrimers, and dendritic-core multi-shell nanotransporters. According to the rapidly increasing research in this field, both in academia and industry, a breakthrough appears likely, once stability problems (nanoparticles) and safety concerns (dendrimers) are overcome. Technical approaches and results of in vitro, ex vivo and in vivo testing are described, taking into account pharmacokinetic, efficacy and safety aspects.
    Handbook of experimental pharmacology 01/2010; 197(197):435-68. DOI:10.1007/978-3-642-00477-3_15
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Actinic keratoses are encountered by physicians worldwide on a daily basis. As these precancerous lesions can transform to skin carcinomas, it is important to understand the many available options to use as treatment. In recent years, new therapeutic options have emerged to treat this common condition. These treatments as well as a review of the literature of conventional therapies will be discussed.
    Clinical, Cosmetic and Investigational Dermatology 09/2010; 3:119-26. DOI:10.2147/CCID.S9910
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract An increasing body of evidence, including epidemiological data, clinical and histopathologic observations, and molecular biological findings, has highlighted the underlying malignant nature of actinic keratosis (AK). Scientific evidence accumulated over the past decade supports the concept that AK should no longer be considered premalignant but instead is now thought to be the earliest stage of a biologic continuum ending in squamous cell carcinoma. This paradigm shift, coupled with a worldwide increase in the incidence of AK, has changed how dermatologists treat AK. These changes include the development of novel topical and procedural therapies; modification of established topical monotherapy regimens to include interval, sequential, short-course, and short-contact therapies; combining various topical therapies; and combining topical and procedural therapies. This review will examine the mechanisms of action and the safety and efficacy data for emerging interval and combination therapies used to treat AK.
    Journal of Dermatological Treatment 10/2011; 22(5):288-97. DOI:10.3109/09546631003797072 · 1.67 Impact Factor
Show more